scholarly journals Serum miR‐182 is a predictive biomarker for dichotomization of risk of hepatocellular carcinoma in rats

2019 ◽  
Vol 58 (11) ◽  
pp. 2017-2025 ◽  
Author(s):  
Merricka C. Livingstone ◽  
Natalie M. Johnson ◽  
Bill D. Roebuck ◽  
Thomas W. Kensler ◽  
John D. Groopman
Keyword(s):  
Hepatocellular Carcinoma ◽  
Predictive Biomarker

CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma

2020 ◽  
Vol 69 (5) ◽  
pp. 825-834
Author(s):  
Qiu-Zhong Pan ◽  
Qing Liu ◽  
Yu-Qing Zhou ◽  
Jing-Jing Zhao ◽  
Qi-Jing Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Predictive Biomarker ◽  
Cell Cytotoxicity ◽  
Cell Immunotherapy ◽  
Cik Cell

scholarly journals Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primary biliary cholangitis patients

10.52586/5042 ◽  
2021 ◽  
Vol 26 (12) ◽  
pp. 1480-1492
Author(s):  
Naohiro Nakamura ◽  
Katsunori Yoshida ◽  
Rinako Tsuda ◽  
Miki Murata ◽  
Takashi Yamaguchi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Risk Assessment ◽  
Predictive Biomarker ◽  
Primary Biliary Cholangitis ◽  
Carcinoma Risk

Quantitative comparison of PD-L1 immuno-histochemical assays in hepatocellular carcinoma: The Blueprint-HCC study.

2018 ◽  
Vol 36 (5_suppl) ◽  
pp. 91-91 ◽  
Author(s):  
David James Pinato ◽  
Francesco A Mauri ◽  
Paolo Spina ◽  
Owen Cain ◽  
Abdul Siddique ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumour Size ◽  
Pairwise Comparison ◽  
Predictive Biomarker ◽  
Chi Square ◽  
Protein Levels ◽  
Tier System ◽  
Chi Square Test ◽  
L1 Protein ◽  
Quantitative Scoring

91 Background: Programmed cell death ligand 1 (PD-L1) expression by immunohistochemistry (IHC) enriches for responses to PD-1/PD-L1 inhibitors, however its role as a predictive biomarker in hepatocellular carcinoma (HCC) is inconclusive, with no consensus on any particular assay. We evaluated the performance of 4 different PD-L1 detection assays previously published in landmark clinical studies. Methods: PD-L1 IHC was performed on 4 serial sections from tissue microarray (TMA) blocks containing 100 archival cases of HCC that included tumour and surrounding non-tumorous tissue. Antibody clones E1LN3, 28-8, 22c3, SP263 were compared on the basis of percentage and intensity of staining in malignant cells (M) to generate an H-score (range 0-300). Immune cells infiltrating (ICI) and at the periphery, in non-tumorous tissue (ICP) were scored on a 4-tier system (0-3). Results: Patients were 76% males, 20% HCV-positive, 64% cirrhotic with a median age of 67 years. Median tumour size was 4 cm, 70% of patients had T1-T2 tumours and 48% were of grade 2. The proportion of PD-L1 positive cases according to M-ICI-ICP pattern was 2-6-2% for E1LN3, 10-18-19% for 28-8, 9-22-18% for 22c3 and 5-14-13% for SP263. Pairwise comparison of M H-scores revealed heterogeneity across antibodies, with highest concordance between E1L3N/SP263 (R2 = 0.95), E1L3N/22c3 (R2 = 0.65), 22c3/SP263 (R2 = 0.66) and increasing discordance for 28-8/22c3 (R2 = 0.44), E1L3N/28-8 (R2 = 0.29), and 28-8/SP263 (R2 = 0.26). Detection of PD-L1-positive immune infiltrates using a semi-quantitative scoring system revealed significantly different scores in pairwise non-parametric comparisons of ICI (p < 0.05) but not ICP (p > 0.05 for chi-square test). Conclusions: In the Blueprint-HCC study we demonstrated that quantification of PD-L1 protein levels in tumour cells, intra-tumoural and peri-tumoural infiltrate is characterised by inter-assay discordance in HCC. This has profound implications in the clinical development of predictive correlates of efficacy to immunotherapy in HCC. Sources of such discordance should be explored.

EXPRESS: Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents

2021 ◽  
pp. 000456322110367
Author(s):  
Ishida Hidekazu ◽  
Masao Takemura ◽  
Atsushi Suetsugu ◽  
Takafumi Naiki ◽  
Takuji Tanaka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Antiviral Treatment ◽  
Predictive Biomarker ◽  
Direct Acting Antiviral ◽  
Control Subjects ◽  
Viral Hepatitis C ◽  
Healthy Control ◽  
Direct Acting

Background: Progranulin (GP88) is an 88-kDa glycoprotein growth factor with important biological effects in tumorigenesis and tumor survival. We investigated the usefulness of measuring serum GP88 (sGP88) levels as a predictive biomarker for hepatocellular carcinoma (HCC) in patients with viral hepatitis C after treatment with direct-acting antiviral (DAA) agents. Methods: We measured the sGP88 levels by using a sandwich enzyme-linked immunoassay from 67 healthy control subjects and 29 patients (20 patients who did not develop HCC and 9 patients who developed HCC after treatment) with viral hepatitis C after treatment with asunaprevir and daclatasvir. Results: The sGP88 levels of patients with chronic hepatitis C prior to antiviral treatment were significantly higher than those of healthy control subjects. After antiviral treatment, the sGP88 levels of patients who eventually developed HCC were significantly higher than those who did not develop HCC. The changes in the sGP88 levels before and after treatment in patients who developed HCC were significantly lower than those in patients who did not develop HCC. The cumulative incidence of HCC was significantly higher in either patients with high sGP88 levels after treatment or those with small changes of sGP88 levels pre- and post-treatment. Conclusions: Sustained high levels of sGP88 in patients treated with DAA agents are correlated with the risk of developing HCC.

scholarly journals CD24 as a Novel Predictive Biomarker in Patients with Hepatocellular Carcinoma: Friend or Foe?

2018 ◽  
Vol 33 (6) ◽  
pp. 542-543
Author(s):  
Nikolaos Machairas ◽  
Diamantis I. Tsilimigras ◽  
Demetrios Moris
Keyword(s):  
Hepatocellular Carcinoma ◽  
Predictive Biomarker
Sign in / Sign up

Export Citation Format

Share Document